Neoadjuvant Treatment with Angiogenesis‐Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes of Radiofrequency Ablation as First-Line Therapy for Hepatocellular Carcinoma less than 3 cm in Potentially Transplantable Patients

(2019) Adam Doyle et al.   JOURNAL OF HEPATOLOGY

Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension

(2019) Jorie Versmissen et al.   CARDIOVASCULAR RESEARCH

Sorafenib for Patients with Hepatocellular Carcinoma and Child‐Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study

(2019) Tim A. Labeur et al.   ONCOLOGIST

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma

(2018) Sadakatsu Ikeda et al.   ONCOLOGIST

Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)

(2018) Yoon Ji Choi et al.   Cancer Research and Treatment

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

(2017) Riccardo Lencioni et al.   JOURNAL OF HEPATOLOGY

The biology of Hepatocellular carcinoma: implications for genomic and immune therapies

(2017) Galina Khemlina et al.   Molecular Cancer

Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma

(2016) Ann-Lii Cheng et al.   HEPATOLOGY

Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial

(2015) Katrin Hoffmann et al.   BMC CANCER

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

(2015) Jordi Bruix et al.   LANCET ONCOLOGY

Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy

(2015) Armin Finkenstedt et al.   LIVER INTERNATIONAL

Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer

(2014) B. Escudier et al.   CLINICAL CANCER RESEARCH

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

(2014) Robert J Motzer et al.   LANCET ONCOLOGY

Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

(2014) M. Ronot et al.   ONCOLOGIST

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

(2013) Y-K Kang et al.   BRITISH JOURNAL OF CANCER

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

(2013) E. Angevin et al.   CLINICAL CANCER RESEARCH

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

(2012) J. M. Llovet et al.   CLINICAL CANCER RESEARCH

Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib

(2012) A. Lachenmayer et al.   CLINICAL CANCER RESEARCH

Population Pharmacokinetic/Pharmacodynamic Modeling to Assist Dosing Schedule Selection for Dovitinib

(2012) Xiaofeng Wang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

(2011) K. B. Kim et al.   CLINICAL CANCER RESEARCH

International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life ques

(2011) Wei-Chu Chie et al.   HEPATOLOGY

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

(2011) Pierre-Alain Clavien et al.   LANCET ONCOLOGY

Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection

(2011) Sabine Irtan et al.   LIVER INTERNATIONAL

Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1-Mediated Inhibition of STAT3

(2011) W.-T. Tai et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis

(2010) J. H. Dey et al.   CANCER RESEARCH

Inhibition of Vascular Endothelial Growth Factor Receptor-1/Wnt/ -catenin Crosstalk Leads to Tumor Cell Death

(2009) B. D. Zeitlin et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE